No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 20.21M | 24.97M | 25.16M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 3.82M | 3.27M | 6.48M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 16.39M | 21.71M | 18.68M |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 |
| Operating Income | -20.21M | -24.97M | -25.16M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -0.24% | -0.01% |
| EBITDA | -20.14M | -24.7M | -23.02M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -0.23% | 0.07% |
| D&A (Non-Cash Add-back) | 63.61K | 272.85K | 2.14M |
| EBIT | -20.14M | -24.7M | -27.3M |
| Net Interest Income | 10.83K | 309.03K | 241.01K |
| Interest Income | 27.03K | 352.67K | 222.29K |
| Interest Expense | 16.2K | 43.64K | -18.72K |
| Other Income/Expense | 47.41K | 229.21K | -2.12M |
| Pretax Income | -20.16M | -24.74M | -27.28M |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 800 |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | -20.16M | -24.74M | -27.29M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -0.23% | -0.1% |
| Net Income (Continuing) | -20.16M | -24.74M | -27.29M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -1.34 | -1.65 | -3.26 |
| EPS Growth % | - | -0.23% | -0.98% |
| EPS (Basic) | -1.34 | -1.65 | -3.26 |
| Diluted Shares Outstanding | 15.03M | 15.03M | 19.51M |
| Basic Shares Outstanding | 15.03M | 15.03M | 19.51M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 20.48M | 3M | 9.21M |
| Cash & Short-Term Investments | 20.45M | 2.96M | 8.64M |
| Cash Only | 20.45M | 2.96M | 8.64M |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 33.75K | 36.91K | 0 |
| Total Non-Current Assets | 0 | 0 | 110.55K |
| Property, Plant & Equipment | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 110.55K |
| Total Assets | 20.48M | 3M | 9.32M |
| Asset Turnover | - | - | - |
| Asset Growth % | - | -0.85% | 2.11% |
| Total Current Liabilities | 4.34M | 6.92M | 8.8M |
| Accounts Payable | 2.13M | 3.42M | 1.92M |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 2.08M | 277.5K | 0 |
| Current Ratio | 4.71x | 0.43x | 1.05x |
| Quick Ratio | 4.71x | 0.43x | 1.05x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 1.31M | 95.7M | 411.76K |
| Long-Term Debt | 404.99K | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 900.76K | 95.7M | 411.76K |
| Total Liabilities | 5.65M | 102.62M | 9.21M |
| Total Debt | 404.99K | 0 | 0 |
| Net Debt | -20.04M | -2.96M | -8.64M |
| Debt / Equity | 0.03x | - | - |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | -1247.33x | -572.26x | - |
| Total Equity | 14.83M | -99.63M | 104.19K |
| Equity Growth % | - | -7.72% | 1% |
| Book Value per Share | 0.99 | -6.63 | 0.01 |
| Total Shareholders' Equity | 14.83M | -99.63M | 104.19K |
| Common Stock | 3 | 2 | 20 |
| Retained Earnings | -80.35M | -105.09M | -132.38M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -17.79M | -21.63M | -21.84M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | -0.22% | -0.01% |
| Net Income | -20.16M | -24.74M | -27.29M |
| Depreciation & Amortization | 0 | 0 | 0 |
| Stock-Based Compensation | 654.07K | 423.54K | 2M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | -20.38K | 123.46K | 2.35M |
| Working Capital Changes | 1.73M | 2.57M | 1.1M |
| Change in Receivables | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 586.26K | 1.29M | -1.5M |
| Cash from Investing | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | 19.26M | 4.13M | 27.53M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 0 | 0 | -1.93M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -17.79M | -21.63M | -21.84M |
| FCF Margin % | - | - | - |
| FCF Growth % | - | -0.22% | -0.01% |
| FCF per Share | -1.18 | -1.44 | -1.12 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.87x | 0.80x |
| Interest Paid | 0 | 0 | 71.03K |
| Taxes Paid | 0 | 0 | 800 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | -135.92% | - | -26189.05% |
| Debt / Equity | 0.03x | - | - |
| Interest Coverage | -1247.33x | -572.26x | - |
| FCF Conversion | 0.88x | 0.87x | 0.80x |
Actuate Therapeutics Inc (ACTU) grew revenue by 0.0% over the past year. Growth has been modest.
Actuate Therapeutics Inc (ACTU) reported a net loss of $24.1M for fiscal year 2024.
Actuate Therapeutics Inc (ACTU) has a return on equity (ROE) of -26189.1%. Negative ROE indicates the company is unprofitable.
Actuate Therapeutics Inc (ACTU) had negative free cash flow of $20.4M in fiscal year 2024, likely due to heavy capital investments.